MBRX - モレキュリン・バイオテック (Moleculin Biotech Inc.) モレキュリン・バイオテック

 MBRXのチャート


 MBRXの企業情報

symbol MBRx
会社名 Moleculin Biotech Inc (モレキュリン・バイオテック)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 Moleculin Biotech Inc. is a preclinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin which it refers to as Annamycin an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). Annamycin is a Phase II clinical-stage anthracycline and liposome formulated anthracycline that has been designed to eliminate cardiotoxicity and avoid the multidrug resistance mechanisms. It has over two other drug development projects in progress one involving a portfolio of small molecules which it refers to as the WP1066 Portfolio focused on the modulation of key oncogenic transcription factors involved in the progression of cancer and the WP1122 Portfolio a suite of molecules targeting the metabolic processes involved in cancer in general and glioblastoma. As of April 3 2017 it had not generated any revenue from its operations.   モレキュリン・バイオテックは米国のバイオ医薬品企業。臨床前と臨床段階において、がん治療薬の開発に焦点を当て、テキサス大学システムのMDアンダ―ソン・がんセンタ―とのライセンス契約に基づく。同社候補薬は「リボソ―ム型Annamycin」で、抵抗性急性脊髄性白血病の治療を目指す。本社はテキサス州ヒュ―ストン。   
本社所在地 5300 Memorial Drive Suite 950 Houston TX 77007 USA
代表者氏名
代表者役職名
電話番号 +1 713-300-5160
設立年月日 42186
市場名 NASDAQ Small Cap
ipoyear 2016年
従業員数
url www.moleculin.com
nasdaq_url https://www.nasdaq.com/symbol/mbrx
adr_tso
EBITDA EBITDA(百万ドル) -13.86700
終値(lastsale) 1.41
時価総額(marketcap) 37874710.77
時価総額 時価総額(百万ドル) 32.50241
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 20.78041
当期純利益 当期純利益(百万ドル) -13.10300
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Moleculin Biotech Inc revenues was not reported. Net loss increased 88% to $7.1M. Higher net loss reflects Research and development increase from $1.2M to $5.5M (expense) Gain from expiration of warrants decrease of 55% to $1M (income) General and administrative increase of 58% to $2.6M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.21 to -$0.28.

 MBRXのテクニカル分析


 MBRXのニュース

   Moleculin Announces Full Exercise of Over-Allotment Option  2021/02/10 21:15:00 PR Newswire
HOUSTON, Feb. 10, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the underwriters of its…
   Moleculin Announces Grant Awarded to Polish Research Institute for Independent Clinical Trial of Annamycin in Sarcoma Lung Metastases  2021/02/08 12:30:00 Benzinga
HOUSTON , Feb. 8, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ: MBRX ) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the Agencja Badań Medycznych (The Medical Research Agency) a Polish state agency responsible for development of scientific research in the field of medical and health sciences, awarded a grant equivalent to $1.5 million USD to the Maria Sklodowska-Curie National Research Institute to fund a Phase 1B /2 clinical trial of Annamycin for the treatment of soft tissue sarcoma (STS) lung metastases. The grant-funded clinical trial will be led by Prof. Piotr Rutkowski , MD, PhD, Head of Department of Soft Tissue/Bone Sarcoma and Melanoma at the Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Poland . Prof. Piotr Rutkowski will be assisted in part, by WPD Pharmaceuticals in Poland , a licensee of Annamycin, who will provide support in preparation for and conduct of the clinical trial, which is expected to begin this year.
   Moleculin Announces Pricing Of $67.8 Million Underwritten Public Offering  2021/02/03 13:30:00 PR Newswire
HOUSTON, Feb. 3, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced the pricing of an underwritten…
   Moleculin to Present at the H.C. Wainwright BioConnect 2021 Conference  2021/01/07 12:30:00 PR Newswire
HOUSTON, Jan. 7, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that members of management will…
   Moleculin To Present Antitumor Activity of Annamycin in Combination with Ara-C in AML at American Society for Hematology Annual Conference  2020/12/03 12:30:00 PR Newswire
HOUSTON, Dec. 3, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it will present animal data…
   Moleculin Announces Full Exercise of Over-Allotment Option  2021/02/10 21:15:00 PR Newswire
HOUSTON, Feb. 10, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the underwriters of its…
   Moleculin Announces Grant Awarded to Polish Research Institute for Independent Clinical Trial of Annamycin in Sarcoma Lung Metastases  2021/02/08 12:30:00 Benzinga
HOUSTON , Feb. 8, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ: MBRX ) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the Agencja Badań Medycznych (The Medical Research Agency) a Polish state agency responsible for development of scientific research in the field of medical and health sciences, awarded a grant equivalent to $1.5 million USD to the Maria Sklodowska-Curie National Research Institute to fund a Phase 1B /2 clinical trial of Annamycin for the treatment of soft tissue sarcoma (STS) lung metastases. The grant-funded clinical trial will be led by Prof. Piotr Rutkowski , MD, PhD, Head of Department of Soft Tissue/Bone Sarcoma and Melanoma at the Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Poland . Prof. Piotr Rutkowski will be assisted in part, by WPD Pharmaceuticals in Poland , a licensee of Annamycin, who will provide support in preparation for and conduct of the clinical trial, which is expected to begin this year.
   Moleculin Announces Pricing Of $67.8 Million Underwritten Public Offering  2021/02/03 13:30:00 PR Newswire
HOUSTON, Feb. 3, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced the pricing of an underwritten…
   Moleculin to Present at the H.C. Wainwright BioConnect 2021 Conference  2021/01/07 12:30:00 PR Newswire
HOUSTON, Jan. 7, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that members of management will…
   Moleculin To Present Antitumor Activity of Annamycin in Combination with Ara-C in AML at American Society for Hematology Annual Conference  2020/12/03 12:30:00 PR Newswire
HOUSTON, Dec. 3, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it will present animal data…
   Moleculin to Present at the H.C. Wainwright BioConnect 2021 Conference  2021/01/07 12:30:00 PR Newswire
HOUSTON, Jan. 7, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that members of management will…
   Moleculin To Present Antitumor Activity of Annamycin in Combination with Ara-C in AML at American Society for Hematology Annual Conference  2020/12/03 12:30:00 PR Newswire
HOUSTON, Dec. 3, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it will present animal data…
   72 Biggest Movers From Yesterday  2020/12/02 09:58:21 Benzinga
Gainers Auris Medical Holding Ltd. (NASDAQ: EARS ) shares jumped 371% to close at $5.23 on Tuesday after the company reported positive efficacy data for its AM-301 in protecting against Sars Covid-19 infections. Corporación América Airports S.A. (NYSE: CAAP ) shares surged 43% to close at $4.49 on Tuesday after the company reported an agreement to extend the Aeropuertos Argentina 2000 concession for 10-years until 2038. Arlo Technologies Inc (NYSE: ARLO ) jumped 31.2% to close at $6.90. Traders are circulating link on Apple Store showing Arlo Ultra 4K wire-free security cameras sold by Apple.. Jaguar Health, Inc. (NASDAQ: JAGX ) shares climbed 30.9% to close at $0.4580 on Tuesday. Jaguar Health shares jumped over 66% on Monday after the company announced plans to develop and commercialize its Crofelemer. CollPlant Biotechnologies Ltd. (NASDAQ: CLGN ) rose 29% to close at $10.23 after the company swung to a profit in the latest quarter. Onconova Therapeutics, Inc. (NASDAQ: ONTX ) shares surged 28.5% to close at $0.3725 after climbing over 11% on Monday.
   FDA Rare Pediatric tags for WP1066 lifts Moleculin Biotech (NASDAQ:MBRX)  2020/12/01 13:55:58 Seeking Alpha
Moleculin Biotech (NASDAQ:MBRX) soars 41% in premarket, after the FDA has designated Rare Pediatric Disease tag for its drug candidate WP1066, for each of
   Thinking about buying stock in Titan Pharmaceuticals, Moderna, Moleculin Biotech, Corbus Pharmaceuticals, or Altimmune?  2020/12/01 13:30:00 PR Newswire
NEW YORK, Dec. 1, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TTNP, MRNA, MBRX, CRBP, and ALT. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….

 関連キーワード  (医薬品 米国株 モレキュリン・バイオテック MBRX Moleculin Biotech Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)